(HLN) Haleon - Overview
Exchange: NYSE •
Country: United Kingdom •
Currency: USD •
Type: Common Stock •
ISIN: US4055521003
Stock: Oral Care, Vitamins, Pain Relief, Cold Relief, Digestive Health
Total Rating 46
Risk 84
Buy Signal -0.91
| Risk 5d forecast | |
|---|---|
| Volatility | 22.8% |
| Relative Tail Risk | 0.07% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.15 |
| Alpha | -3.70 |
| Character TTM | |
|---|---|
| Beta | -0.122 |
| Beta Downside | -0.150 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.11% |
| CAGR/Max DD | 0.45 |
EPS (Earnings per Share)
Revenue
Description: HLN Haleon March 04, 2026
Haleon plc develops, manufactures, and sells consumer healthcare products globally. Its portfolio includes oral health, vitamin/mineral/supplement (VMS), and over-the-counter (OTC) medicines.
The company operates across North America, Europe, the Middle East, Africa, Latin America, and Asia Pacific. This broad geographic reach is common for established consumer health companies seeking diversified revenue streams.
Key brands include Sensodyne (oral health), Centrum (VMS), Theraflu (respiratory), Voltaren (pain relief), and Tums (digestive health). The consumer healthcare sector often relies on strong brand recognition to drive sales.
Haleon was founded in 1715 and changed its name from DRVW 2022 plc in February 2022. For further detailed analysis, consider exploring ValueRay.
Headlines to watch out for
- Consumer health product demand drives revenue growth
- Raw material costs impact profit margins
- Regulatory approvals crucial for new product launches
- Global economic slowdown reduces discretionary spending
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 2.78b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.48 > 1.0 |
| NWC/Revenue: -1.98% < 20% (prev -31.14%; Δ 29.16% < -1%) |
| CFO/TA 0.17 > 3% & CFO 5.43b > Net Income 2.78b |
| Net Debt (7.27b) to EBITDA (4.76b): 1.53 < 3 |
| Current Ratio: 0.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.48b) vs 12m ago -1.77% < -2% |
| Gross Margin: 63.76% > 18% (prev 0.61%; Δ 6.31k% > 0.5%) |
| Asset Turnover: 57.63% > 50% (prev 49.42%; Δ 8.22% > 0%) |
| Interest Coverage Ratio: 7.61 > 6 (EBITDA TTM 4.76b / Interest Expense TTM 557.5m) |
Altman Z'' 5.37
| A: -0.01 (Total Current Assets 4.54b - Total Current Liabilities 4.92b) / Total Assets 32.57b |
| B: 0.85 (Retained Earnings 27.80b / Total Assets 32.57b) |
| C: 0.13 (EBIT TTM 4.24b / Avg Total Assets 33.44b) |
| D: 1.73 (Book Value of Equity 27.89b / Total Liabilities 16.12b) |
| Altman-Z'' Score: 5.37 = AAA |
Beneish M -3.14
| DSRI: 0.98 (Receivables 2.12b/1.90b, Revenue 19.27b/16.96b) |
| GMI: 0.96 (GM 63.76% / 61.43%) |
| AQI: 0.86 (AQ_t 0.80 / AQ_t-1 0.93) |
| SGI: 1.14 (Revenue 19.27b / 16.96b) |
| TATA: -0.08 (NI 2.78b - CFO 5.43b) / TA 32.57b) |
| Beneish M-Score: -3.14 (Cap -4..+1) = AA |
What is the price of HLN shares?
As of March 14, 2026, the stock is trading at USD 10.00 with a total of 7,847,316 shares traded.
Over the past week, the price has changed by -2.43%, over one month by -10.45%, over three months by +2.03% and over the past year by +0.24%.
Over the past week, the price has changed by -2.43%, over one month by -10.45%, over three months by +2.03% and over the past year by +0.24%.
Is HLN a buy, sell or hold?
Haleon has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy HLN.
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HLN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.9 | 19.3% |
| Analysts Target Price | 11.9 | 19.3% |
HLN Fundamental Data Overview March 09, 2026
P/E Trailing = 20.9796
P/E Forward = 19.2308
P/S = 4.1511
P/B = 2.0871
P/EG = 2.4357
Revenue TTM = 19.27b USD
EBIT TTM = 4.24b USD
EBITDA TTM = 4.76b USD
Long Term Debt = 7.58b USD (from longTermDebt, two quarters ago)
Short Term Debt = 834.5m USD (from shortTermDebt, last quarter)
Debt = 8.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.27b USD (from netDebt column, last quarter)
Enterprise Value = 53.06b USD (45.79b + Debt 8.59b - CCE 1.32b)
Interest Coverage Ratio = 7.61 (Ebit TTM 4.24b / Interest Expense TTM 557.5m)
EV/FCF = 19.25x (Enterprise Value 53.06b / FCF TTM 2.76b)
FCF Yield = 5.19% (FCF TTM 2.76b / Enterprise Value 53.06b)
FCF Margin = 14.30% (FCF TTM 2.76b / Revenue TTM 19.27b)
Net Margin = 14.43% (Net Income TTM 2.78b / Revenue TTM 19.27b)
Gross Margin = 63.76% ((Revenue TTM 19.27b - Cost of Revenue TTM 6.99b) / Revenue TTM)
Gross Margin QoQ = 65.03% (prev 64.51%)
Tobins Q-Ratio = 1.63 (Enterprise Value 53.06b / Total Assets 32.57b)
Interest Expense / Debt = 1.90% (Interest Expense 163.0m / Debt 8.59b)
Taxrate = 19.50% (208.7m / 1.07b)
NOPAT = 3.42b (EBIT 4.24b * (1 - 19.50%))
Current Ratio = 0.92 (Total Current Assets 4.54b / Total Current Liabilities 4.92b)
Debt / Equity = 0.52 (Debt 8.59b / totalStockholderEquity, last quarter 16.40b)
Debt / EBITDA = 1.53 (Net Debt 7.27b / EBITDA 4.76b)
Debt / FCF = 2.64 (Net Debt 7.27b / FCF TTM 2.76b)
Total Stockholder Equity = 16.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.31% (Net Income 2.78b / Total Assets 32.57b)
RoE = 17.26% (Net Income TTM 2.78b / Total Stockholder Equity 16.11b)
RoCE = 17.91% (EBIT 4.24b / Capital Employed (Equity 16.11b + L.T.Debt 7.58b))
RoIC = 13.55% (NOPAT 3.42b / Invested Capital 25.20b)
WACC = 4.84% (E(45.79b)/V(54.38b) * Re(5.46%) + D(8.59b)/V(54.38b) * Rd(1.90%) * (1-Tc(0.19)))
Discount Rate = 5.46% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.56%
[DCF] Terminal Value 88.43% ; FCFF base≈2.47b ; Y1≈3.05b ; Y5≈5.20b
[DCF] Fair Price = 32.35 (EV 151.34b - Net Debt 7.27b = Equity 144.07b / Shares 4.45b; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 8.23 | EPS CAGR: 104.2% | SUE: -0.01 | # QB: 0
Revenue Correlation: 58.42 | Revenue CAGR: 23.63% | SUE: -0.14 | # QB: 0
EPS current Year (2026-12-31): EPS=0.56 | Chg7d=+0.005 | Chg30d=+0.005 | Revisions Net=+2 | Growth EPS=+9.0% | Growth Revenue=+3.5%
EPS next Year (2027-12-31): EPS=0.60 | Chg7d=+0.001 | Chg30d=+0.001 | Revisions Net=+2 | Growth EPS=+8.3% | Growth Revenue=+4.7%
P/E Forward = 19.2308
P/S = 4.1511
P/B = 2.0871
P/EG = 2.4357
Revenue TTM = 19.27b USD
EBIT TTM = 4.24b USD
EBITDA TTM = 4.76b USD
Long Term Debt = 7.58b USD (from longTermDebt, two quarters ago)
Short Term Debt = 834.5m USD (from shortTermDebt, last quarter)
Debt = 8.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.27b USD (from netDebt column, last quarter)
Enterprise Value = 53.06b USD (45.79b + Debt 8.59b - CCE 1.32b)
Interest Coverage Ratio = 7.61 (Ebit TTM 4.24b / Interest Expense TTM 557.5m)
EV/FCF = 19.25x (Enterprise Value 53.06b / FCF TTM 2.76b)
FCF Yield = 5.19% (FCF TTM 2.76b / Enterprise Value 53.06b)
FCF Margin = 14.30% (FCF TTM 2.76b / Revenue TTM 19.27b)
Net Margin = 14.43% (Net Income TTM 2.78b / Revenue TTM 19.27b)
Gross Margin = 63.76% ((Revenue TTM 19.27b - Cost of Revenue TTM 6.99b) / Revenue TTM)
Gross Margin QoQ = 65.03% (prev 64.51%)
Tobins Q-Ratio = 1.63 (Enterprise Value 53.06b / Total Assets 32.57b)
Interest Expense / Debt = 1.90% (Interest Expense 163.0m / Debt 8.59b)
Taxrate = 19.50% (208.7m / 1.07b)
NOPAT = 3.42b (EBIT 4.24b * (1 - 19.50%))
Current Ratio = 0.92 (Total Current Assets 4.54b / Total Current Liabilities 4.92b)
Debt / Equity = 0.52 (Debt 8.59b / totalStockholderEquity, last quarter 16.40b)
Debt / EBITDA = 1.53 (Net Debt 7.27b / EBITDA 4.76b)
Debt / FCF = 2.64 (Net Debt 7.27b / FCF TTM 2.76b)
Total Stockholder Equity = 16.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.31% (Net Income 2.78b / Total Assets 32.57b)
RoE = 17.26% (Net Income TTM 2.78b / Total Stockholder Equity 16.11b)
RoCE = 17.91% (EBIT 4.24b / Capital Employed (Equity 16.11b + L.T.Debt 7.58b))
RoIC = 13.55% (NOPAT 3.42b / Invested Capital 25.20b)
WACC = 4.84% (E(45.79b)/V(54.38b) * Re(5.46%) + D(8.59b)/V(54.38b) * Rd(1.90%) * (1-Tc(0.19)))
Discount Rate = 5.46% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.56%
[DCF] Terminal Value 88.43% ; FCFF base≈2.47b ; Y1≈3.05b ; Y5≈5.20b
[DCF] Fair Price = 32.35 (EV 151.34b - Net Debt 7.27b = Equity 144.07b / Shares 4.45b; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 8.23 | EPS CAGR: 104.2% | SUE: -0.01 | # QB: 0
Revenue Correlation: 58.42 | Revenue CAGR: 23.63% | SUE: -0.14 | # QB: 0
EPS current Year (2026-12-31): EPS=0.56 | Chg7d=+0.005 | Chg30d=+0.005 | Revisions Net=+2 | Growth EPS=+9.0% | Growth Revenue=+3.5%
EPS next Year (2027-12-31): EPS=0.60 | Chg7d=+0.001 | Chg30d=+0.001 | Revisions Net=+2 | Growth EPS=+8.3% | Growth Revenue=+4.7%